Why the latest soquelitinib data matters for Corvus Pharmaceuticals (CRVS) Corvus Pharmaceuticals (CRVS) just reported positive cohort 4 Phase 1 data for soquelitinib in moderate to severe atopic ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...

Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthmaPositive opinion from the ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...

A study published in Nutrition Reviews in November 2025 found evidence linking oral probiotics and synbiotics to improvements in atopic dermatitis (AD) symptoms. However, research for other skin ...

New real-world evidence highlights lebrikizumab’s effectiveness and safety in atopic dermatitis. Discover how patients ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product ...

In this video interview, Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at the Northwestern ...